- Home
- Industry Solutions
- Services
- Support
- About Us
Creative Biolabs is an experienced and excellent provider of data validation and project evaluation for stem cell therapy. We are committed to providing comprehensive project management and high-quality data verification services for your stem cell therapy project. We are pleased to use our extensive experience and advanced platform to provide the best services to meet every need of our customers.
ESCs are pluripotent stem cells that are derived from the inner cell mass of a blastocyst, an early-stage preimplantation embryo. They are taken from embryos in a very early stage of development and have two important properties: they have the ability to replicate infinitely through simple division (self-renewal) and to differentiate into any cell type (pluripotency) in the human body. These characteristics not only open up new prospects for regenerative medicine but also for the study of genetic diseases and the development of new treatments.
Due to their plasticity and potentially unlimited capacity for self-renewal, ESCs therapy offers great promise for new medical treatments. This technology involves obtaining healthy and functional specialized cells from ESCs, then injecting them into a patient to regenerate an organ or restore organ function. ESCs have been proposed for treating intractable diseases such as diabetes, spinal cord injuries, neurodegenerative and cardiovascular diseases. ESC therapy can be used to regenerate organs or produce substances necessary to restore biological functions. However, translating the potential of ESCs into treatments has been challenging because of the safety and technical issues.
The two main challenges in the translation of ESCs to clinical applications are teratoma formation by residual undifferentiated ESCs in the cell preparation and immune rejection of ESC-derived cells or tissues due to incompatible HLA profiles of ESC and recipient (Fig.1).
To reduce the risk of teratoma formation, several physical or biological methods have been developed to remove residual ESCs. Some physical methods are based on magnetic- or fluorescence-activated cell sorters (MACS or FACS) that can sort cells with ESC-associated surface markers, SSEA-4 and TRA-1-60 or on cellular density using discontinuous gradients of Percoll or PureSperm. Additionally, residual ESCs can be destroyed using a cytotoxic antibody specific for undifferentiated ESCs.
To prevent immune rejection, one strategy is to establish an ESCs repository to carry lines expressing HLA combinations compatible with all possible haplotypes in the population. Moreover, donor cell tolerance can be induced by manipulating host immune defenses, such as eliminating donor-reactive T cells in the thymus, producing tolerogenic dendritic cells and inducing Treg cells.
Fig.1 Reduce tumor formation and immune rejection. (Yeo, 2011)
To ensure the authenticity and accuracy of the data in your stem cell therapy project, we provide accurate and cost-effective data verification and data validation services. Our highly skilled and experienced data verification team can help you keep your data consistent and authenticate. Creative Biolabs can perform any scale data verification or validation project that covers all stages of stem cell therapy development. In addition, to meet the challenging requirements, we provide comprehensive project solutions and expert consultation for your scientific research, including but not limited to:
At Creative Biolabs, all projects are worth considering, regardless of size or complexity. With abundant experience in stem cell research, our scientists are dedicated to fulfilling your data validation needs and addressing any challenges in stem cell therapy development. If you have any questions about our ESCs services, please feel free to contact us.
